Last reviewed · How we verify
Herpes simplex dendritic keratitis
Approved treatments
- Vidarabin
- Cytovene · Roche Palo
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Herpes simplex dendritic keratitis patent landscape — cliff calendar, originator estates, attackable patents
- Herpes simplex dendritic keratitis treatment landscape brief
- Herpes simplex dendritic keratitis treatment updates RSS
Frequently asked questions about Herpes simplex dendritic keratitis
What drugs treat Herpes simplex dendritic keratitis?
Tracked treatments include Vidarabin, Cytovene.
What is the treatment for Herpes simplex dendritic keratitis?
Standard treatment for Herpes simplex dendritic keratitis includes Vidarabin, Cytovene. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Herpes simplex dendritic keratitis patent cliff · Herpes simplex dendritic keratitis CI report
- Treatment: Vidarabin
- Treatment: Cytovene · Roche Palo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing